Journal Mobile Options
Table of Contents
Vol. 34, No. 8-9, 2011
Issue release date: September 2011
Onkologie 2011;34:461–466
(DOI:10.1159/000331062)

Continuous Treatment in Multiple Myeloma – Ready for Prime Time?

Knop S.
Medizinische Klinik und Poliklinik II, Schwerpunkt Hämatologie und Onkologie, Universitätsklinikum Würzburg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Recently, non-genotoxic drugs have succeeded in several hematologic malignancies such as chronic myeloid leukemia (CML) or indolent non-Hodgkin’s lymphomas. Unlike this, alkylating chemotherapy is still a backbone of anti-myeloma drug treatment in the vast majority of ‘medically fit’ subjects. With the introduction of the immunomodulatory drugs thalidomide and lenalidomide, a novel class of compounds was integrated into therapy of multiple myeloma. Either drug may be delivered for a prolonged time; however fatigue, constipation and neuropathy prevent thalidomide from serving as a ‘continuous’ treatment. Lenalidomide has been approved for treatment of relapsed multiple myeloma, to be delivered as a continuous therapy. Since the drug lacks thalidomide’s severe side effects, it is being explored on a continuous maintenance basis both after conventional therapy and after autologous stem cell transplantation. Preliminary data of respective clinical trials that have become available show highly significant differences in event-free survival times, favoring continuous lenalidomide over placebo. Currently, it is still unclear whether this will translate also into an overall survival benefit after prolonged follow-up.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50